The ABCB1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T-lymphocyte line, featuring disruption of the ATP-binding cassette subfamily B member 1 (ABCB1) gene. This polyclonal knockout model abolishes expression of P-glycoprotein (P-gp), a transmembrane efflux transporter implicated in multidrug resistance. The CRISPR/Cas9-mediated gene disruption introduces loss-of-function mutations across the cell population, generating a heterogeneous yet effective knockout system for studying drug transport without relying on clonal isolation. Researchers benefit from a pooled knockout population that retains the parental line??s proliferative capacity while eliminating confounding P-gp activity.
The parental Jurkat cell line is a human acute T-cell leukemia-derived model, widely employed in immunology and cancer biology due to its immortalized growth and well-characterized signaling networks. Jurkat cells endogenously express functional P-gp, making them a relevant platform for investigating ABC transporter-mediated drug resistance in T-cell malignancies. Their use in apoptosis, T-cell receptor signaling, and HIV research further broadens the experimental scope, allowing ABCB1 knockout studies to be integrated into diverse assay formats.
ABCB1 encodes P-gp, an ATP-dependent efflux pump with broad substrate specificity, actively exporting hydrophobic compounds including chemotherapeutic agents such as doxorubicin, paclitaxel, and vinblastine. P-gp expression is transcriptionally regulated by nuclear receptors PXR (NR1I2) and CAR (NR1I3), as well as by NF-??B, TP53, Wnt/??-catenin signaling. At the plasma membrane, P-gp localizes within lipid rafts and interacts with scaffold proteins Caveolin-1 and Ezrin, CD44, and the chaperone Hsp70, which together modulate its stability and function. P-gp reduces intracellular drug accumulation, inhibiting apoptosis. Knockout of ABCB1 disrupts this efflux mechanism, leading to increased retention of P-gp substrates and potentiation of drug-induced cytotoxicity.
In the Jurkat T-lymphoblast background, ABCB1 knockout provides a powerful tool to dissect P-gp-specific contributions to multidrug resistance without interference from other ABC transporters. The polyclonal knockout population enables robust, population-level measurements in efflux assays and cytotoxicity screens, while avoiding clonal artifacts. This model is valuable for studying pharmacoresistance in T-cell leukemias and lymphomas, where P-gp overexpression correlates with poor outcomes. Moreover, the Jurkat background permits manipulation of T-cell receptor or apoptosis pathways to explore crosstalk with drug resistance.
Key applications include measuring P-gp transport kinetics with Rhodamine 123 or Calcein-AM efflux assays and ATPase activity assays to assess inhibitor interactions. The knockout cells are ideal for profiling the cytotoxicity of known P-gp substrates like doxorubicin, enabling determination of P-gp-dependent resistance. They also serve as a negative control for pharmacological inhibitor screening. Additional techniques such as Western blot and RT-qPCR validate P-gp loss, while flow cytometry for surface expression confirms membrane clearance. These cells support multidrug resistance mechanism studies, substrate identification, and drug sensitivity profiling. For technical details or custom applications, contact Ascent Research.
